This study involves single doses of LY3154207 and will evaluate the effects of LY3154207 on the body. There will be 3 parts to this study. Part A will test single increasing doses of LY3154207 and will last approximately 7 weeks for each participant. Each participant will receive two doses of LY3154207, if part A is completed. Part B will test a single dose of LY3154207 and will last approximately 5 weeks for each participant. Part B includes collecting fluid from the spinal column to measure levels of LY3154207. Part C will include a single dose of LY3154207 given alone and then a second dose given along with itraconazole to look for change in LY3154207 levels. Part C will last about 3 weeks for each participant. Participants may only enroll in 1 of the 3 parts of the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
64
Administered orally
Administered orally
Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
PRA Health Sciences
Salt Lake City, Utah, United States
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Up to 48 hours after administration of study drug
Pharmacokinetics (PK) Plasma Part A : Maximum Drug Concentration (Cmax) of LY3154207
Time frame: Predose through 48 hours after administration of study drug
Pharmacokinetics (PK) Plasma Part A: Area Under the Concentration Curve (AUC) of LY3154207
Time frame: Predose through 48 hours after administration of study drug
Pharmacokinetics (PK) Cerebrospinal Fluid (CSF) Part B: Area Under the Concentration Time Curve (AUC) of LY3154207
Time frame: Predose through 48 hours after administration of study drug
Pharmacokinetics (PK) Cerebrospinal Fluid (CSF) Part B: Maximum Drug Concentration (Cmax) of LY3154207
Time frame: Predose through 48 hours after administration of study drug
Pharmacokinetics (PK) Plasma Part C: Area Under the Concentration Time Curve (AUC) of LY3154207 when Co-administered with Itraconazole
Time frame: Predose through 96 hours after administration of study drug
Pharmacokinetics (PK) Plasma Part C: Maximum Drug Concentration (Cmax) of LY3154207 when Co-administered with Itraconazole
Time frame: Predose through 96 hours after administration of study drug
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.